Pulmonary Drug Delivery Systems Market Size to Worth USD 92.4 BN by 2030

The global pulmonary drug delivery systems market was estimated at USD 51.87 billion in 2021, and it is expected to be worth around USD 92.4 billion by 2030 with a CAGR of 6.6% in next 10 years.

Latest Report Study on “Pulmonary Drug Delivery Systems Market - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030”.

Pulmonary drug delivery system is targeted drug delivery, which deals with the respiratory tract. It is a device used for administration of drugs through the pulmonary route for the treatment of the respiratory diseases. Due to an increase in the respiratory diseases such as obstructive pulmonary disease, cystic fibrosis, asthma, all of these happen to be the reason for a growth in the market for the pulmonary drug delivery systems. Around 262,000,000 people were affected with asthma across the globe in the year 2019.

Get the sample copy of report@ https://www.precedenceresearch.com/sample/1502

Due to extended exposure to harmful gases, the rising pollution levels and exposure to tobacco fumes are all the reasons for the increasing prevalence of respiratory diseases. The easy availability of the pulmonary drug delivery devices and the awareness among the general public has increased the demand. Innovative product offerings are playing an important role in the market growth.

Scope of the Report

Regional Snapshot

North America is the biggest market for pulmonary drug delivery systems market. Due to the prevailing pulmonary disease patients in US, There is an increased demand for pulmonary drug delivery system. As there is an increased awareness regarding the management of these chronic conditions with the help of high healthcare expenditure there is a growth in this market. The Asia Pacific market is also expected to grow the highest CAGR during the forecast. An increase in the population and increased urbanization has resulted in increasing pollution levels. Polluted air is a major cause of these diseases. About 80% of the deaths due to COPD occur in the low and middle income countries, according to the WHO.

Request here for customization@ https://www.precedenceresearch.com/customization/1502

Market Dynamics

Drivers

The increased prevalence of the chronic obstructive pulmonary disease is will be responsible for the growth of the global pulmonary drug delivery systems market during the forecast. The existence of the COPD in Latin America ranges between 6.2 to 19.6% in individuals that are aged above 40. The market is expected to grow due to the advantages associated with the drug delivery route, it provides ease of administration, it requires low amount of drug as compared to the oral dosage and a very negligible or a very less side effect. Also it helps in the quick onset of action. It targets the organ and the drug degradation by liver is avoided. So there is larger absorption by the lungs. The increase in the geriatric population was also expected to do drive the market growth of the pulmonary drug delivery systems.

Restraints

The government's regulatory scenario, which happens to be very stringent, is expected to hinder the growth of the market. The rules and regulations regarding this market are quite challenging. As MDIS and DPI's are considered a drug device combination product there are legal constraints and various immunological barriers, along with mechanical and chemical barriers that limit the growth of the market the pulmonary drug delivery system is a new system as compared to the other ones and many people are not aware of the advantages of using this system, so it may restrain the growth of the market.

Opportunities

In 2020, researchers from Hungary reported the development of a carrier based DPI system which has a suitable shape and size for the pulmonary application. There is various research and developments in the dry powder inhalation which is expected to provide growth opportunities for this market. The use of vibrating mesh nebulizers used in therapeutics that ensures the optimum level of aerosol drug delivery is also expected to help in the growth of the market.

Challenges

There is a low efficiency of the inhalation system, the aerosol systems need to produce optimum size particles, and otherwise they may be exhaled. The drug absorption may also be limited due to a physical barrier like the mucus and the interactions of drugs with the mucus.

Report Highlights

• Based on the product segment the metered dose inhaler segment had a largest market share of around 66% in the year 2020 and it is expected to grow during the forecast. There is a high product acceptance among the consumers which has led to the growth.
• Based on the indication segments ASTMA is the leading segment. The changes in the lifestyle and urbanization are a major reason behind the rising patients. Easily available pulmonary drug delivery systems have improved the market over the past years. Allergic rhinitis is boosting the revenues of this segment due to the availability of nasal sprays, allergy shots and dry powder inhalers.
• On the basis of the distribution channel, the hospital pharmacy segment is dominating the global pulmonary drug delivery systems market. As there is a good availability of pulmonary drug delivery devices in the hospitals, this has become a good choice. Hospitals are able to provide extensive care and good quick treatments which have contributed to the increased demand.

Browse more related reports@ https://www.precedenceresearch.com/industry/healthcare

Recent Developments

• A device named adhero that tracks the usage pattern of the metered dose inhalers by the COPD patients was introduced by Lupin in 2019
• Glenmark Pharmaceuticals Limited introduced latest inhalers in 2019.one metered dosed inhale named Soprobec and another breathe actuated inhaler named Stalpex.

Market Segmentation

By Product

• Dry Powder Inhalers
• Nebulizers
• Metered Dose Inhalers
• Accessories

By Indication

• COPD
• Asthma
• Cystic Fibrosis
• Allergic Rhinitis
• Others

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Click Here to View Full Report Table of Contents

Buy this Research Report@ https://www.precedenceresearch.com/checkout/1502

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333